Peptides · Peptide comparison
Relaxin-2 (Serelaxin) vs Thymosin Beta-4
Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Cardiovascular Function
Heart Failure Support
Acute Medical Management
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical data
Compound specifications
Relaxin-2 (Serelaxin)
- Molecular formula
- C256H408N74O74S8
- Molecular weight
- 5,963 Da (Daltons)
- Half-life
- Varies by route of administration
- Bioavailability
- Varies by route of administration
- CAS number
- See PubChem for identifiers
Thymosin Beta-4
- Molecular formula
- C212H350N56O78S
- Molecular weight
- 4963
- Half-life
- Dose-dependent (increases with higher doses)
- Bioavailability
- 100% (subcutaneous and intravenous)
- CAS number
- 77591-33-4
Protocols
Dosing compared
Relaxin-2 (Serelaxin)
Intravenous
- 30 mcg/kg/dayContinuous IV infusion · 48 hoursWeight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only.
Thymosin Beta-4
Subcutaneous injection
- 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
- 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
- 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Applications
Best suited for
Relaxin-2 (Serelaxin)
- Acute heart failure symptom management
- Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area [5][9].
- Cardiovascular recovery and support
- Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area [2].
- Hospital-based therapeutic interventions
- Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area [3][15].
Thymosin Beta-4
- Post-Surgery Recovery
- Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
- Chronic Wound Management
- Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
- Tissue Regeneration
- Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety profile
Side effects
Relaxin-2 (Serelaxin)
Common
- Hypotension (low blood pressure) - most common
- Tachycardia (increased heart rate)
- Headache
- Nausea
- Dizziness
- Peripheral edema (swelling)
- Increased creatinine levels
- Hyperkalemia (high potassium)
- Syncope (fainting)
- Atrial fibrillation
- Blood pressure checks every 2-4 hours during infusion
- Kidney function (creatinine and eGFR)
- Electrolytes, particularly potassium
- Heart rate and cardiac rhythm
- Urine output
Serious
- Severe cardiovascular events
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research status
Safety & evidence
Relaxin-2 (Serelaxin)
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. [3][5][9] Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. [11] Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response [12].
Contraindications
- Severe hypotension or hemodynamic instability
- Pregnancy (despite relaxin's natural role)
- Acute kidney injury or severe renal dysfunction
- Recent myocardial infarction (within 7 days)
- Uncontrolled arrhythmias
Thymosin Beta-4
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Decision guide
Which is right for you?
Relaxin-2 (Serelaxin)
Choose Relaxin-2 (Serelaxin) if…
- Acute heart failure symptom management
- Cardiovascular recovery and support
- Hospital-based therapeutic interventions
Thymosin Beta-4
Choose Thymosin Beta-4 if…
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation